Analysis of immune reconstitution after autologous CD34 + stem/progenitor cell transplantation for systemic sclerosis: Predominant reconstitution of Th1 CD4 + t cells

Rheumatology

Volumn 50, Issue 5, 2011, Pages 944-952

  Tsukamoto, Hiroshi ^a   Nagafuji, Koji ^a   Horiuchi, Takahiko ^a   Mitoma, Hiroki ^a   Niiro, Hiroaki ^a   Arinobu, Yojiro ^b   Inoue, Yasushi ^a   To, Kentaro ^a   Miyamoto, Toshihiro ^a   Iwasaki, Hiromi ^b   Teshima, Takanori ^b   Harada, Mine ^a,c   Akashi, Koichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Autoimmune disease; High dose cyclophosphamide; Immune reconstitution; Th1 Th2 balance; Transplantation

Indexed keywords

CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; GLYCOPROTEIN; PROTEIN KL 6; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SCL 70 ANTIBODY; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; INTERSTITIAL PNEUMONIA; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCLERODERMA; SYSTEMIC SCLEROSIS; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ADULT; ANTIBODIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MUCIN-1; NUCLEAR PROTEINS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; REMISSION INDUCTION; SCLERODERMA, SYSTEMIC; TH1 CELLS; TREATMENT OUTCOME;

EID: 79955133066     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq414     Document Type: Article

References (33)

1. LeRoy EC, Black CM, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1998;15:202-5.
2. Yurovsky VV. The repertoire of T-cell receptors in systemic sclerosis. Crit Rev Immunol 1995;15:155-65.
3. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
4. Hough RE, Snowden JA, Wulffraat NM. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol 2005;128:432-59.
5. McSweeney PA, Nash RA, Sullivan KM et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002;100:1602-10.
6. Nash RA, McSweeney PA, Crofford LJ et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007;110:1388-96.
7. Farge D, Passweg J, van Laar JM et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004;63:974-81.
8. Vonk MC, Marjanovic Z, van den Hoogen FH et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008;67:98-104.
9. Bohgaki T, Atsumi T, Bohgaki M et al. Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression. J Rheumatol 2009;36:1240-8.
10. Oyama Y, Barr WG, Statkute L et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transpl 2007;40:549-55.
11. Tsukamoto H, Nagafuji K, Horiuchi T et al. Phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006;65:508-14.
12. Burt RK, Marmont A, Oyama Y et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006;54:3750-60.
13. Muraro PA, Douek DC, Packer A et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005;201:805-16.
14. Farge D, Henegar C, Carmagnat M et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 2005;52:1555-63.
15. Shen Y, Ichino M, Nakazawa M, Minami M. CpG oligodeoxynucleotides prevent the development of scleroderma-like syndrome in tight-skin mice by stimulating a Th1 immune response. J Invest Dermatol 2005; 124:1141-8.
16. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006;33:275-84.
17. Akahoshi M, Nakashima H, Tanaka Y et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999;42:1644-8.
18. Kohno K, Nagafuji K, Tsukamoto H et al. Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Transpl Infect Dis 2009;11:318-23.
19. Ohnishi H, Yokoyama A, Kondo K et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002;165:378-81.
20. Kuroki Y, Takahashi H, Chiba H, Akino T. Surfactant proteins A and D: disease markers. Biochim Biophys Acta 1998;1408:334-45.
21. Alexander T, Thiel A, Rosen O et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009;113:214-23.
22. + immune regulatory network. Blood 2006;107:1696-702.
23. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004;50: 1918-27.
24. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992;35: 67-72.
25. Mavalia C, Scaletti C, Romagnani P et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751-8.
26. Serpier H, Gillery P, Salmon-Ehr V et al. Antagonistic effects of interferon-gamma and interleukin-4 on fibroblast cultures. J Invest Dermatol 1997;109:158-62.
27. Mueller R, Krahl T, Sarvetnick N. Tissue-specific expression of interleukin-4 induces extracellular matrix accumulation and extravasation of B cells. Lab Invest 1997;76: 117-28.
28. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kaliński P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000;164:4507-12.
29. Brinkman DM, de Kleer IM, ten Cate R et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum 2007;56:2410-21.
30. Storek J, Zhao Z, Lin E et al. Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). Clin Immunol 2004;113:285-98.
31. Hu PQ, Fertig N, Medsger TA Jr, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003;48:1363-73.
32. Sakkas LI. New developments in the pathogenesis of systemic sclerosis. Autoimmunity 2005;38:113-6.
33. Scala E, Pallotta S, Frezzolini A et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6.